Glofitamab (Glofit) plus R-CHOP has a favorable safety profile and induces high response rates in patients with previously untreated (1L) large B-cell lymphoma (LBCL) defined as high risk by circulating tumor DNA (ctDNA) dynamics: Preliminary safety and efficacy results Meeting Abstract
| Authors: | Falchi, L.; Jardin, F.; Haioun, C.; Wrobel, T.; Mészáros Joergensen, J.; Bastos-Oreiro, M.; Mou, E.; Martinez-Lopez, J.; Budde, L. E.; Bartlett, N. L.; Zaucha, J. M.; Garcia-Sancho, A. M.; Shah, R.; Rees, N.; McCord, R.; Bazeos, A.; Tandon, M.; Doral, M.; Troy-Barnes, E.; Nijland, M. |
| Abstract Title: | Glofitamab (Glofit) plus R-CHOP has a favorable safety profile and induces high response rates in patients with previously untreated (1L) large B-cell lymphoma (LBCL) defined as high risk by circulating tumor DNA (ctDNA) dynamics: Preliminary safety and efficacy results |
| Meeting Title: | 65th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 142 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Dec 9-12 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-11-02 |
| Start Page: | 858 |
| Language: | English |
| ACCESSION: | WOS:001159306703127 |
| DOI: | 10.1182/blood-2023-173953 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
